If you already have an account please use the link below to sign in. If you have any problems with your access or would like to request an individual access account please contact our customer service ...

You are currently accessing unquote.com via your Enterprise account. If you already have an account please use the link below to sign in. If you have any problems with your access or would like to ...

If you already have an account please use the link below to sign in. If you have any problems with your access or would like to request an individual access account please contact our customer service ...

If you already have an account please use the link below to sign in. If you have any problems with your access or would like to request an individual access account please contact our customer service ...

If you already have an account please use the link below to sign in. If you have any problems with your access or would like to request an individual access account please contact our customer service ...

If you already have an account please use the link below to sign in. If you have any problems with your access or would like to request an individual access account please contact our customer service ...

If you already have an account please use the link below to sign in. If you have any problems with your access or would like to request an individual access account please contact our customer service ...

Gillespie joins Stirling from AMP Capital. She has prior experience at UBS, Credit Suisse and Bridgepoint. In her new role, she will be responsible for recruitment and developing human capital within ...

Audacia had been an investor in PNY since 2013. Company Headquartered in Paris and founded in 2012, PNY is a burger restaurants operator.... , Exits, France, Consumer , France, Trade sale ...

The company is expected to be marketed off an EBITDA in the region of EUR 40m to EUR 50m, said two of the sources, although one of them noted that a portion of that is from a deep M&A pipeline. Corus ...

Initial bids for the business were due last week, said one of the sources. Permira already owns Neuraxpharm, a specialty pharma company focused on the treatment of the central nervous system (CNS), ...

The deal values the company at around £300m. A source close to the situation told Unquote the firm generated a 6.6x return. SpaMedica is to be merged with Ober Scharrer Group, a Germany-based ...